TGFB1 and cardiac hypertrophy: PY administration interferes positively with several intracellular pathways, such as lowering activation of the TGFβ1/TAK1 pathway, which is directly involved in cardiac hypertrophy and fibrosis17, and improving acetylcholine-induced vascular reactivity by increasing NO39.